Program
ferric maltol
Also written as “Ferric Maltol”, “Ferric maltol suspension” and “Ferric maltol”.
Its studies are mostly in Anemia, Iron-Deficiency · Anemia · Iron Deficiencies · Renal Insufficiency, Chronic, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Shield Therapeutics | 70 open or running | phase 3since Apr 19, 2011 | Apr 19, 2011 | none ahead |
| Beijing Aosaikang Pharmaceutical | 10 open or running | phase 3since Jul 22, 2026 | Jul 22, 2026 | none ahead |
Also a collaborator on its studies: medpace-inc.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 19, 2011First study: phase 3 study in Anemia, Iron-DeficiencyNew to Shield TherapeuticsShield Therapeutics · NCT01340872 · 128 enrolled
- May 10, 2011Phase 3 study in Anemia, Iron-DeficiencyShield Therapeutics · NCT01352221 · 128 enrolled
- Feb 9, 2016Phase 3 study in Anemia, Iron-DeficiencyShield Therapeutics · NCT02680756 · 250 enrolled · United States, Belgium, France and more
- Aug 30, 2016Phase 3 study in Renal Insufficiency, ChronicShield Therapeutics · NCT02968368 · 167 enrolled · United States
- May 23, 2017Phase 1 study in Iron DeficienciesShield Therapeutics · NCT03181451 · 37 enrolled · United Kingdom
- Oct 22, 2020Phase 1 study in Anemia, Iron-DeficiencyShield Therapeutics · NCT04626414 · 32 enrolled · United States
- Oct 27, 2021Phase 3 study in AnemiaShield Therapeutics · NCT05126901 · 65 enrolled · United States, Puerto Rico, United Kingdom
- Jul 22, 2026Beijing Aosaikang Pharmaceutical's first study: phase 3 study in Anemia, Iron-DeficiencyNew to Beijing Aosaikang PharmaceuticalBeijing Aosaikang Pharmaceutical · NCT07739368 · 122 enrolled · China
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 8 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07739368Anemia, Iron-Deficiency · China | 3 | Completed | Beijing Aosaikang Pharmaceutical | Feb 20, 2025 | 122 |
| NCT05126901Anemia · United States, Puerto Rico, United Kingdom | 3 | Completed | Shield Therapeutics | Jun 9, 2024 | 65 |
| NCT04626414Anemia, Iron-Deficiency · United States | 1 | Completed | Shield Therapeutics | Nov 13, 2020 | 32 |
| NCT03181451Iron Deficiencies · United Kingdom | 1 | Completed | Shield Therapeutics | Mar 28, 2018 | 37 |
| NCT02968368Renal Insufficiency, Chronic · United States | 3 | Completed | Shield Therapeutics | Jan 18, 2018 | 167 |
| NCT02680756Anemia, Iron-Deficiency · United States, Belgium, France and more | 3 | Completed | Shield Therapeutics | Oct 2018 | 250 |
| NCT01352221Anemia, Iron-Deficiency | 3 | Completed | Shield Therapeutics | Oct 2013 | 128 |
| NCT01340872Anemia, Iron-Deficiency | 3 | Completed | Shield Therapeutics | Oct 2013 | 128 |
How it is read
Names in the registry
- “Ferric Maltol”, 4 entries
- “Ferric maltol suspension”, 1 entry
- “Ferric maltol”, 1 entry
- “ST10-021”, 1 entry
- “ST10”, 1 entry
Codes read as this program: ST10.
Conditions, from the studies’ own filings
- Anemia, Iron-Deficiency, 5 studies
- Anemia, 1 study
- Iron Deficiencies, 1 study
- Renal Insufficiency, Chronic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.